drugset / Trial / NCT07126665
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, open-label, multicenter Phase I/II study of MHB088C combined with MHB039A in patients with advanced malignant solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB088C and MHB039A combination therapy.
Timeline
- Start
- 2025-09-18
- Primary completion
- 2029-08
- Completion
- 2031-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MHB039A | Unknown | — | Intravenous |
| Subject | MHB088C | Monoclonal antibody | — | Intravenous |